U.K. drug development outfit Ergomed has come out the other end of its London IPO, touting a range of R&D partnerships that give it a chance to share the rewards of its clients' work.
The recently IPO'd Catalent has signed a deal with biotech Cingulate Therapeutics to help develop a duo of candidates for ADHD, tapping its expertise in crafting controlled-release tablets.
Germany's Evotec has joined a trio of research projects focused on multiple sclerosis, contributing its developmental know-how to some early-stage R&D.
Indian CRO GVK Biosciences is working to get back in the good graces of European regulators after inspectors found evidence that its employees doctored clinical trial results.
PPD is buying up the entirety of X-Chem, which operates as a biotech within a CRO, marking a vote of confidence in the continued demand for drug discovery services.
TransCelerate BioPharma, a nonprofit founded by the world's biggest drugmakers to make R&D more efficient, is encouraging developers to adopt risk-based monitoring for clinical trials, disclosing its thinking in two research papers.
Pennsylvania CRO FlowMetric is zeroing in on companion diagnostics, launching a new company to put its platform technology to use in developing tests.
The Association of Clinical Research Organizations, which represents the world's largest CROs, polled its membership and found that the industry's biggest players have seen their revenues and payrolls skyrocket over the past decade, claiming an increasingly large share of global R&D spends.
PCI, a contract pharma packaging company, has snapped up clinical trial supply operation Biotec, expanding its footprint across all phases of drug development.
Covance is teaming up with Frenova Renal Research, an arm of dialysis magnate Fresenius Medical Care, tapping the organization's expansive database to spotlight the most effective treatments for patients with kidney ailments.
Risk-sharing researcher Evotec wants what it's due, mounting a legal challenge to reclaim some outstanding royalties after a biotech buyout scandal left it high and dry.
Trialbee, a Swedish patient-recruitment outfit, has added AstraZeneca to its client roster, bringing its direct-to-patient technology to the U.K. drugmaker.
Quintiles, the world's largest CRO, is dialing up its focus on nascent drugmakers, launching a biotech-focused service offering designed to meet the particular needs of the industry's seedlings without losing them in the Big Pharma shuffle.
Risk-sharing researcher Evotec took a blow last week when partner Hyperion Therapeutics pulled the plug on a diabetes trial, but the German company is keeping things moving, expanding an agreement that will put it to work on treatments for Huntington's disease.
CRO magnate Icon and and eClinical outfit Medidata are pooling their resources to offer a combined platform for patient-reported outcomes in clinical trials, touting their technology as faster and more effective in surveying participants.
Nonprofit researcher SRI International has struck a deal with Japanese drugmaker Nobelpharma to collaborate on a new treatment for the painful gynecological disease endometriosis.
PRA is planning to cap months of dealmaking with a Wall Street splash, filing to go public and bank $375 million in the process.
European CRO Venn Life Sciences has agreed to pitch in on a major international study of a new stent that harmlessly dissolves in the body.
Ricerca Bioscience is looking to get bought, and if it can't, the Ohio-headquartered CRO is clearing the way for massive layoffs.
TransCelerate BioPharma, a nonprofit founded by some of the world's biggest drugmakers, is looking to standardize how the industry protects patient privacy when sharing data.